Paediatric drug development of ramipril: reformulation, in vitro and in vivo evaluation

Craig Russell, Sumyra Begum, Yasar Hussain, Majad Hussain, David Huen, Ayesha S Rahman, Yvonne Perrie, Afzal R. Mohammed

Research output: Contribution to journalArticle

Abstract

Ramipril is used mainly for the treatment of hypertension and to reduce incidence of fatality following heart attacks in patients who develop indications of congestive heart failure. In the paediatric population it is used most commonly for the treatment of heart failure, hypertension in type 1 diabetes and diabetic nephropathy. Due to the lack of a suitable liquid formulation, the current study evaluates the development of a range of oral liquid formulations of ramipril along with their in vitro and in vivo absorption studies. Three different formulation development approaches were studied: solubilisation using acetic acid as a co-solvent, complexation with hydroxypropyl-β-cyclodextrin (HP-β-CD) and suspension development using xanthan gum. Systematic optimisation of formulation parameters for the different strategies resulted in the development of products stable for twelve months at long term stability conditions. In vivo evaluation showed CMAX of 10.48 µg/mL for co-solvent, 13.04µg/ml for the suspension and 29.58µg/mL for the cyclodextrin based ramipril solution. Interestingly, both ramipril solution (co-solvent) and the suspension showed a TMAX of 2.5h, however, cyclodextrin based ramipril produced TMAX at 0.75h following administration. The results presented in this study provide translatable products for oral liquid ramipril which offer preferential paediatric use over existing alternatives.
LanguageEnglish
Pages854-863
Number of pages10
JournalJournal of Drug Targeting
Volume23
Issue number9
Early online date7 May 2015
DOIs
Publication statusPublished - 2015

Fingerprint

Ramipril
Pediatrics
Pharmaceutical Preparations
Suspensions
Cyclodextrins
Heart Failure
Hypertension
Diabetic Nephropathies
Treatment Failure
Type 1 Diabetes Mellitus
Acetic Acid
In Vitro Techniques
Myocardial Infarction
Incidence
Population

Bibliographical note

This is an Accepted Manuscript of an article published by Taylor & Francis in Journal of Drug Targeting on 7/5/15, available online: http://wwww.tandfonline.com/10.3109/1061186X.2015.1036275

Funding: BBSRC (BB/H016716/1).

Keywords

  • Caco2
  • liquid formulation
  • oral drug delivery
  • ramipril

Cite this

Russell, Craig ; Begum, Sumyra ; Hussain, Yasar ; Hussain, Majad ; Huen, David ; Rahman, Ayesha S ; Perrie, Yvonne ; Mohammed, Afzal R. / Paediatric drug development of ramipril : reformulation, in vitro and in vivo evaluation. In: Journal of Drug Targeting. 2015 ; Vol. 23, No. 9. pp. 854-863.
@article{3eec4303cf3842a183bcd04350609085,
title = "Paediatric drug development of ramipril: reformulation, in vitro and in vivo evaluation",
abstract = "Ramipril is used mainly for the treatment of hypertension and to reduce incidence of fatality following heart attacks in patients who develop indications of congestive heart failure. In the paediatric population it is used most commonly for the treatment of heart failure, hypertension in type 1 diabetes and diabetic nephropathy. Due to the lack of a suitable liquid formulation, the current study evaluates the development of a range of oral liquid formulations of ramipril along with their in vitro and in vivo absorption studies. Three different formulation development approaches were studied: solubilisation using acetic acid as a co-solvent, complexation with hydroxypropyl-β-cyclodextrin (HP-β-CD) and suspension development using xanthan gum. Systematic optimisation of formulation parameters for the different strategies resulted in the development of products stable for twelve months at long term stability conditions. In vivo evaluation showed CMAX of 10.48 µg/mL for co-solvent, 13.04µg/ml for the suspension and 29.58µg/mL for the cyclodextrin based ramipril solution. Interestingly, both ramipril solution (co-solvent) and the suspension showed a TMAX of 2.5h, however, cyclodextrin based ramipril produced TMAX at 0.75h following administration. The results presented in this study provide translatable products for oral liquid ramipril which offer preferential paediatric use over existing alternatives.",
keywords = "Caco2, liquid formulation, oral drug delivery, ramipril",
author = "Craig Russell and Sumyra Begum and Yasar Hussain and Majad Hussain and David Huen and Rahman, {Ayesha S} and Yvonne Perrie and Mohammed, {Afzal R.}",
note = "This is an Accepted Manuscript of an article published by Taylor & Francis in Journal of Drug Targeting on 7/5/15, available online: http://wwww.tandfonline.com/10.3109/1061186X.2015.1036275 Funding: BBSRC (BB/H016716/1).",
year = "2015",
doi = "10.3109/1061186X.2015.1036275",
language = "English",
volume = "23",
pages = "854--863",
journal = "Journal of Drug Targeting",
issn = "1061-186X",
publisher = "Informa Healthcare",
number = "9",

}

Paediatric drug development of ramipril : reformulation, in vitro and in vivo evaluation. / Russell, Craig; Begum, Sumyra; Hussain, Yasar; Hussain, Majad; Huen, David; Rahman, Ayesha S; Perrie, Yvonne; Mohammed, Afzal R.

In: Journal of Drug Targeting, Vol. 23, No. 9, 2015, p. 854-863.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Paediatric drug development of ramipril

T2 - Journal of Drug Targeting

AU - Russell, Craig

AU - Begum, Sumyra

AU - Hussain, Yasar

AU - Hussain, Majad

AU - Huen, David

AU - Rahman, Ayesha S

AU - Perrie, Yvonne

AU - Mohammed, Afzal R.

N1 - This is an Accepted Manuscript of an article published by Taylor & Francis in Journal of Drug Targeting on 7/5/15, available online: http://wwww.tandfonline.com/10.3109/1061186X.2015.1036275 Funding: BBSRC (BB/H016716/1).

PY - 2015

Y1 - 2015

N2 - Ramipril is used mainly for the treatment of hypertension and to reduce incidence of fatality following heart attacks in patients who develop indications of congestive heart failure. In the paediatric population it is used most commonly for the treatment of heart failure, hypertension in type 1 diabetes and diabetic nephropathy. Due to the lack of a suitable liquid formulation, the current study evaluates the development of a range of oral liquid formulations of ramipril along with their in vitro and in vivo absorption studies. Three different formulation development approaches were studied: solubilisation using acetic acid as a co-solvent, complexation with hydroxypropyl-β-cyclodextrin (HP-β-CD) and suspension development using xanthan gum. Systematic optimisation of formulation parameters for the different strategies resulted in the development of products stable for twelve months at long term stability conditions. In vivo evaluation showed CMAX of 10.48 µg/mL for co-solvent, 13.04µg/ml for the suspension and 29.58µg/mL for the cyclodextrin based ramipril solution. Interestingly, both ramipril solution (co-solvent) and the suspension showed a TMAX of 2.5h, however, cyclodextrin based ramipril produced TMAX at 0.75h following administration. The results presented in this study provide translatable products for oral liquid ramipril which offer preferential paediatric use over existing alternatives.

AB - Ramipril is used mainly for the treatment of hypertension and to reduce incidence of fatality following heart attacks in patients who develop indications of congestive heart failure. In the paediatric population it is used most commonly for the treatment of heart failure, hypertension in type 1 diabetes and diabetic nephropathy. Due to the lack of a suitable liquid formulation, the current study evaluates the development of a range of oral liquid formulations of ramipril along with their in vitro and in vivo absorption studies. Three different formulation development approaches were studied: solubilisation using acetic acid as a co-solvent, complexation with hydroxypropyl-β-cyclodextrin (HP-β-CD) and suspension development using xanthan gum. Systematic optimisation of formulation parameters for the different strategies resulted in the development of products stable for twelve months at long term stability conditions. In vivo evaluation showed CMAX of 10.48 µg/mL for co-solvent, 13.04µg/ml for the suspension and 29.58µg/mL for the cyclodextrin based ramipril solution. Interestingly, both ramipril solution (co-solvent) and the suspension showed a TMAX of 2.5h, however, cyclodextrin based ramipril produced TMAX at 0.75h following administration. The results presented in this study provide translatable products for oral liquid ramipril which offer preferential paediatric use over existing alternatives.

KW - Caco2

KW - liquid formulation

KW - oral drug delivery

KW - ramipril

UR - http://www.scopus.com/inward/record.url?scp=84944686575&partnerID=8YFLogxK

U2 - 10.3109/1061186X.2015.1036275

DO - 10.3109/1061186X.2015.1036275

M3 - Article

VL - 23

SP - 854

EP - 863

JO - Journal of Drug Targeting

JF - Journal of Drug Targeting

SN - 1061-186X

IS - 9

ER -